Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has shared an update.
Lumos Diagnostics has announced a partnership with MedPro Associates to expand sales coverage for their FebriDx test across the USA. This collaboration aims to increase awareness and adoption of the FebriDx test, which distinguishes between bacterial and non-bacterial infections, by leveraging MedPro’s extensive network and expertise in healthcare markets.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics specializes in rapid, point-of-care diagnostic technologies, offering customized assay development, manufacturing services, and proprietary digital reader platforms. They focus on developing and commercializing tests targeting infectious and inflammatory diseases.
YTD Price Performance: -5.00%
Average Trading Volume: 2,061,130
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$28.44M
For a thorough assessment of LDX stock, go to TipRanks’ Stock Analysis page.
